<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00366925</url>
  </required_header>
  <id_info>
    <org_study_id>Ada-UC-05-102</org_study_id>
    <nct_id>NCT00366925</nct_id>
  </id_info>
  <brief_title>CESA 5.10 Investigation to Compare the Efficacy and Safety of the Adacolumn® Apheresis Device in Patients With Active Ulcerative Colitis</brief_title>
  <official_title>Randomized Controlled Multicenter Investigation to Compare the Efficacy and Safety of Adacolumn® Granulocytes, Monocytes/Macrophage Apheresis Device, 5 Versus 10 Treatments, in Patients With Active Ulcerative Colitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Frankfurt Research Institute GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otsuka Frankfurt Research Institute GmbH</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the safety and efficacy of 5 Adacolumn® treatments
      over 5 weeks to 10 treatments (two Adacolumn® apheresis treatments during the first 2 weeks,
      followed by 6 weeks with one Adacolumn® apheresis treatment) in patients with active
      ulcerative colitis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Anticipated">174</enrollment>
  <condition>Ulcerative Colitis</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Adacolumn®</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18-75 years old

          2. Active ulcerative colitis documented by clinical symptoms, endoscopic findings and
             histology (in patient history)

          3. Moderate to severe active ulcerative colitis at baseline evaluation, defined as
             follows:

               -  Clinical activity idex (CAI) score &gt; 6; and

               -  Stool frequency score of 2 or 3

          4. Colonic involvement with ulcerative colitis beyond 15 cm of the anal verge

          5. Ulcerative colitis for at least 3 months

          6. Adequate peripheral venous access to allow for completion of the apheresis treatments,
             as demonstrated by the ability to successfully undergo a brief venous access procedure

          7. Receiving one or more of the following medical therapies:

               -  Sulfasalazine, mesalamine and other 5-aminosalicylic acid (5-ASA) agents for 4
                  weeks or more with a stable dose for the last 2 weeks

               -  A maximum of 20 mg per day of prednisone with a stable dose for the last 2 weeks,
                  or

               -  6-mercaptopurine or azathioprine for 12 weeks or more with a stable dose for the
                  last 4 weeks; OR

             Have not received the above medical therapies due to intolerance or demonstrated
             non-response for the time periods specified below:

               -  Sulfasalazine, mesalamine and other 5-ASA agents for 2 weeks

               -  Prednisone for 2 weeks, or

               -  6-mercaptopurine or azathioprine for 4 weeks

          8. For female subjects of child-bearing potential, a negative pregnancy test and
             agreement to use an effective contraceptive method or abstain from sexual intercourse
             during the course of the clinical investigation

          9. Agree to participate in the required follow-up visits

         10. Able to complete the diary

         11. Signed written informed consent document

        Exclusion Criteria:

          1. Febrile (&gt; 38ºC)

          2. Evidence of toxic megacolon

          3. Anticipated need for surgery within 12 weeks

          4. Known obstructive diseases of the gastrointestinal system

          5. Proctocolectomy, total colectomy, ileostomy, stoma or ileal pouch-anal anastomosis

          6. A history of allergic reaction to heparin or heparin-induced thrombocytopenia

          7. A history of hypersensitivity reaction associated with an apheresis procedure or
             intolerance of apheresis procedures

          8. Requires a central venous access catheter for the apheresis treatments

          9. Known infection with enteric pathogens, pathogenic ova or parasites, or a positive
             assay for C. difficile toxin

         10. Hypotension (systolic blood pressure &lt; 90 mmHg and/or diastolic blood pressure &lt; 65
             mmHg) at screening visit only

         11. Uncontrolled hypertension (systolic blood pressure &gt; 180 mmHg or diastolic blood
             pressure &gt; 120 mmHg) despite medical therapy at screening visit only

         12. A history of myocardial infarction or unstable angina within the past 6 months

         13. A history of coronary artery bypass grafting surgery or angioplasty within the past 6
             months

         14. A history of physical findings compatible with a cerebrovascular accident

         15. Congestive heart failure (New York Heart Association Class III or IV)

         16. Prosthetic heart valve, pacemaker or other permanent implant

         17. Severe cardiovascular or peripheral vascular disease

         18. Liver disease defined as levels of SGOT [AST], SGPT [ALT] or alkaline phosphatase &gt;
             2.5x the upper limit of the normal range for the laboratory performing test

         19. History of cirrhosis

         20. Renal insufficiency, defined as serum creatinine &gt; 150% of the upper limit of the
             normal range for the laboratory performing the test

         21. Insulin-dependent type I or type II diabetes. (Patients receiving oral antidiabetic
             treatment can be included.)

         22. Known bleeding disorder (PT or PTT &gt; 1.5x the upper limit of the normal range for the
             laboratory performing the test), or concomitant anticoagulant therapy for purposes
             other than apheresis treatment

         23. Prior history suggestive of a hypercoagulable disorder, including 1 or more episodes
             of pulmonary embolism or deep vein thrombosis

         24. Known infection with hepatitis B or C, or HIV

         25. Abnormal hematology parameters defined as severe anemia with hemoglobin &lt; 8.5 g/dL,
             white blood cell count of &lt; 3,500/ul and a granulocyte count &lt; 2,000/μl

         26. Fibrinogen level &gt; 700 mg/dL

         27. Major surgery within the past 6 weeks

         28. Infection:

               -  Active infections less than 4 weeks from successful completion of antibiotic
                  treatment for routine bacterial infection

               -  Febrile viral infection within 4 weeks of entry into the clinical investigation

               -  Less than 12 weeks from conclusion of therapy for systemic fungal infections

         29. Malignancy within the past 2 years other than surgically cured skin carcinoma or
             cervical dysplasia (CIN I-II)

         30. History of dysplasia or carcinoma of the colon

         31. Current drug or alcohol abuse

         32. Pregnant, lactating or planning to become pregnant during the course of the clinical
             investigation

         33. Used within the last 30 days, an investigational drug, biologic or device or 5 half
             lives, if known, for any investigational drug or biologic

         34. Received cyclosporine or tacrolimus within the last 4 weeks

         35. Received infliximab within the last 8 weeks

         36. Received oral budesonide within the last 2 weeks

         37. Used topical therapy for ulcerative colitis within the last 2 weeks

         38. Previously received Adacolumn® treatments
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Axel Dignass, Prof. Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Markus-Krankenhaus, Frankfurt am Main</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Markus-Krankenhaus</name>
      <address>
        <city>Frankfurt am Main</city>
        <state>Hessen</state>
        <zip>60431</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 21, 2006</study_first_submitted>
  <study_first_submitted_qc>August 21, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2006</study_first_posted>
  <last_update_submitted>April 27, 2009</last_update_submitted>
  <last_update_submitted_qc>April 27, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 28, 2009</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

